Ruo-Fan Ding

Ruo-Fan Ding

Auto-generated profile, based on publicly available information

Ruo-Fan Ding

Institutes of Biomedical Sciences, Inner Mongolia University , Hohhot 010070

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RDRuofan Ding
Ruofan Ding
QWQixuan Wang
Qixuan Wang
LGLihai Gong
Lihai Gong
TZTing Zhang
Ting Zhang
XZXudong Zou
Xudong Zou
LLLei Li
Lei Li
Genome-wide association studies (GWAS) have identified numerous genetic variants associated with diseases and traits. However, the functional interpretation of these variants remains challenging. Expression quantitative trait loci (eQTLs) have been widely used to identify mutations linked to disease, yet they explain only 20–50% of disease-related variants. Single-cell eQTLs (sc-eQTLs) studies provide an immense opportunity to identify new disease risk genes with expanded eQTL scales and transcriptional regulation at a much finer resolution. However, there is no comprehensive database dedicated to single-cell eQTLs that users can use to search, analyse and visualize them. Therefore, we developed the scQTLbase (http://bioinfo.szbl.ac.cn/scQTLbase), the first integrated human sc-eQTLs portal, featuring 304 datasets spanning 57 cell types and 95 cell states. It contains ∼16 million SNPs significantly associated with cell-type/state gene expression and ∼0.69 million disease-associated sc-eQTLs from 3 333 traits/diseases. In addition, scQTLbase offers sc-eQTL search, gene expression visualization in UMAP plots, a genome browser, and colocalization visualization based on the GWAS dataset of interest. scQTLbase provides a one-stop portal for sc-eQTLs that will significantly advance the discovery of disease susceptibility genes.

10 April 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
MZMing-Xiao Zhao
Ming-Xiao Zhao
RDRuo-Fan Ding
Ruo-Fan Ding
QCQiang Chen
Qiang Chen
JMJunhua Meng
Junhua Meng
FLFulai Li
Fulai Li
YZYufen Zhao
Yufen Zhao
Protein N-phosphorylation is widely present in nature and participates in various biological functions. However, current knowledge on N-phosphorylation is extremely limited compared to that on O-phosphorylation. In this study, we collected 11,710 experimentally verified N-phosphosites of 7344 proteins from 39 species and subsequently constructed the database Nphos to share up-to-date information on protein N-phosphorylation. Upon these substantial data, we characterized the sequential and structural features of protein N-phosphorylation. Moreover, after comparing of hundreds of learning models, we chose and optimized gradient boosting decision tree (GBDT) models to predict three types of human N-phosphorylation, achieving mean areas under the receiver operating characteristic curve (AUC) of 90.56%, 91.24%, and 92.01% for pHis, pLys, and pArg, respectively. Meanwhile, we discovered 488,825 distinct N-phosphosites in the human proteome. The models were also deployed in Nphos for interactive N-phosphosite prediction. In summary, this work provides new insights and points for both flexible and focused investigations of N-phosphorylation. It will also facilitate a deeper and more systematic understanding of protein N-phosphorylation modification by providing a data and technical foundation. Nphos is freely available at http://www.bio-add.org and http://ppodd.org.cn/Nphos/.

3 May 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
QYQi-Xuan Yue
Qi-Xuan Yue
RDRuo-Fan Ding
Ruo-Fan Ding
WCWei-Hao Chen
Wei-Hao Chen
LWLv-Ying Wu
Lv-Ying Wu
KLKe Liu
Ke Liu
Zhiliang JiZhiliang Ji
Zhiliang Ji
Background: Adverse drug reactions (ADRs), which are the phenotypic manifestations of clinical drug toxicity in humans, are a major concern in precision clinical medicine. A comprehensive evaluation of ADRs is helpful for unbiased supervision of marketed drugs and for discovering new drugs with high success rates. Objective: In current practice, drug safety evaluation is often oversimplified to the occurrence or nonoccurrence of ADRs. Given the limitations of current qualitative methods, there is an urgent need for a quantitative evaluation model to improve pharmacovigilance and the accurate assessment of drug safety. Methods: In this study, we developed a mathematical model, namely the Adverse Drug Reaction Classification System (ADReCS) severity-grading model, for the quantitative characterization of ADR severity, a crucial feature for evaluating the impact of ADRs on human health. The model was constructed by mining millions of real-world historical adverse drug event reports. A new parameter called Severity_score was introduced to measure the severity of ADRs, and upper and lower score boundaries were determined for 5 severity grades. Results: The ADReCS severity-grading model exhibited excellent consistency (99.22%) with the expert-grading system, the Common Terminology Criteria for Adverse Events. Hence, we graded the severity of 6277 standard ADRs for 129,407 drug-ADR pairs. Moreover, we calculated the occurrence rates of 6272 distinct ADRs for 127,763 drug-ADR pairs in large patient populations by mining real-world medication prescriptions. With the quantitative features, we demonstrated example applications in systematically elucidating ADR mechanisms and thereby discovered a list of drugs with improper dosages. Conclusions: In summary, this study represents the first comprehensive determination of both ADR severity grades and ADR frequencies. This endeavor establishes a strong foundation for future artificial intelligence applications in discovering new drugs with high efficacy and low toxicity. It also heralds a paradigm shift in clinical toxicity research, moving from qualitative description to quantitative evaluation.

23 August 2024 in Genomics, Proteomics & Bioinformatics
Verified
Journal Article
Open access
PDF file
YZYuwei Zhang
Yuwei Zhang
LGLihai Gong
Lihai Gong
RDRuofan Ding
Ruofan Ding
WCWenyan Chen
Wenyan Chen
HRHao Rong
Hao Rong
QLQi Liao
Qi Liao
Growing evidence supports the transcription of enhancer RNAs (eRNAs) and their important roles in gene regulation. However, their interactions with other biomolecules and their corresponding functionality remain poorly understood. In an attempt to facilitate mechanistic research, this study presents eRNA-IDO, the first integrative computational platform for the identification, interactome discovery, and functional annotation of human eRNAs. eRNA-IDO comprises two modules: eRNA-ID and eRNA-Anno. Functionally, eRNA-ID can identify eRNAs from de novo assembled transcriptomes. eRNA-ID includes eight kinds of enhancer makers, enabling users to customize enhancer regions flexibly and conveniently. In addition, eRNA-Anno provides cell-/tissue-specific functional annotation for both new and known eRNAs by analyzing the eRNA interactome from prebuilt or user-defined networks between eRNAs and protein-coding genes. The prebuilt networks include the Genotype-Tissue Expression (GTEx)-based co-expression networks in normal tissues, The Cancer Genome Atlas (TCGA)-based co-expression networks in cancer tissues, and omics-based eRNA-centric regulatory networks. eRNA-IDO can facilitate research on the biogenesis and functions of eRNAs. The eRNA-IDO server is freely available at http://bioinfo.szbl.ac.cn/eRNA_IDO/.

12 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KXKewei Xiong
Kewei Xiong
RDRuofan Ding
Ruofan Ding
YQYangmei Qin
Yangmei Qin
XZXudong Zou
Xudong Zou
JWJiguang Wang
Jiguang Wang
LLLei Li
Lei Li
Accurately deciphering tumor cellular heterogeneity is crucial for developing effective treatments. While single-cell epigenomics assays offer powerful insights into studying tumor heterogeneity beyond the transcriptional level, their application remains a significant challenge. To address this, we introduce Multimodal-based Analysis of scATAC-Seq data (MAAS), a method designed to identify functional tumor cell subpopulations and reconstruct their lineages from single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq). MAAS uniquely integrates multimodal information, encompassing chromatin accessibility, copy number variations (CNVs), and single-nucleotide variants, through self-expressive multimodal matrix factorization. MAAS outperforms existing methods in accuracy and robustness on both simulated and real datasets. When applied to multiple glioma scATAC-seq datasets, MAAS uncovered a previously hidden tumor cell subpopulation resistant to temozolomide treatment. Furthermore, MAAS effectively detected clinically relevant subpopulations with low CNVs, such as those found in pediatric ependymoma and B-cell lymphoma. Additionally, we developed a novel MAAS-derived clinical signature that provides superior prognostic prediction than traditional clinicopathologic features across multiple cancer types. In summary, MAAS significantly advances the identification of clinically relevant tumor cell subpopulations, thereby accelerating the discovery of potential therapeutic targets.

5 October 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MZMing-Xiao Zhao
Ming-Xiao Zhao
RDRuo-Fan Ding
Ruo-Fan Ding
QCQiang Chen
Qiang Chen
JMJunhua Meng
Junhua Meng
FLFulai Li
Fulai Li
YZYufen Zhao
Yufen Zhao
Protein N -phosphorylation widely present in nature and participates in various biological functions. However, current knowledge on N -phosphorylation is extremely limited compared to that on O -phosphorylation. In this study, we collected 11,710 experimentally verified N -phosphosites of 7344 proteins from 39 species and subsequently constructed the database Nphos to share up-to-date information on protein N -phosphorylation. Upon these substantial data, we characterized the sequential and structural features of protein N -phosphorylation. Moreover, after comparing of hundreds of learning models, we chose and optimized gradient boosting decision tree (GBDT) models to predict three types of human N -phosphorylation, achieving mean areas under the receiver operating characteristic curve (AUC) of 90.56%, 91.24%, and 92.01% for pHis, pLys, and pArg, respectively. Meanwhile, we discovered 488,825 distinct N -phosphosites in the human proteome. The models were also deployed in Nphos for interactive N -phosphosite prediction. In summary, this work provides new insights and points for both flexible and focused investigations of N -phosphorylation. It will also facilitate a deeper and more systematic understanding of protein N -phosphorylation modification by providing a data and technical foundation. Nphos is freely available at http://www.bio-add.org and http://ppodd.org.cn/Nphos/ .